Zofenopril: A review of the evidence of its benefits in hypertension and acute myocardial infarction

Clinical Drug Investigation

Volumn 20, Issue 5, 2000, Pages 371-384

  Borghi, Claudio ^a   Ambrosioni, Ettore ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOLYTIC AGENT; PLACEBO; ZOFENOPRIL;

ACUTE HEART INFARCTION; AMBULATORY MONITORING; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FIBRINOLYTIC THERAPY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0033710791     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020050-00008     Document Type: Review

References (43)

1. Disposition of zofenopril calcium in healthy subjects
2. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers
3. Preclinical profile of zofenopril: An angiotensin converting enzyme inhibitor with peculiar cardioprotective properties
4. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and non-sulfhydryl-containing Ace inhibitors
5. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: Possible involvement of the ATP-sensitive potassium channel
6. Converting enzyme inhibitors and the role of the sufhydryl group in the potentiation of exo- and endogenous nitrovasodilators
7. The angiotensin converting enzyme inhibitor zofenoprilat prevents endothelial cell apoptosis and promotes coronary angiogenesis 'in vitro'
8. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors
9. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: Insight into its mechanism of action
10. Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog
11. The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig
12. Report on the comparative effects of zofenopril (SQ 26,991) and captopril on angiotensin-induced pressor responses in normal male subjects. Data on file
13. Evaluation of the angiotensin converting enzyme inhibition activity of zofenopril following administration of three oral ascending doses to healthy volunteers. Data on file
14. Report on the effect of zofenopril calcium on regional blood flow in patients with essential hypertension. Data on file
15. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
16. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
17. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
18. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
19. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy
20. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
21. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension
22. Once-daily zofenopril provides 24-hour ambulatory blood pressure control in hypertensive patients aged under 65 years
23. Comparative evaluation of the anti-hypertensive effect of zofenopril - An angiotensin converting enzyme inhibitor - Versus atenolol, in the treatment of mild to moderate essential hypertension. Multicentre, double-blind, randomised, parallel-group study. Data on file
24. The efficacy and safety of zofenopril compared to amlodipine in patients with mild to moderate hypertension
25. Comparison of the efficacy of zofenopril or enalapril in patients with mild to moderate hypertension. Data on file
26. Study of the duration of action of zofenopril in the treatment of mild to moderate essential arterial hypertension. Data on file
27. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
28. Outcome results of the of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
29. Effect of angiotensin-converting-enzyme inhibitor compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
30. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction
31. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
32. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
33. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension
34. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: Safety considerations
35. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
36. ISIS-4: Randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction
37. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients
38. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study
39. Comparison between the safety profile of Zofenopril and Lisinopril in patients with acute myocardial infarction
40. Effects of captopril on ischaemic events after MI. Results of the Survival and Ventricular Enlargement trial
41. A clinical trial of the ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
42. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-I)
43. Indications for ACE inhibitors in the early treatment of acute myocardial infaction: Systematic review of individual data from 100,000 patients in randomized trials